Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company, offers rapid, intelligent, and non-invasive testing solutions. On May 29, the company announced its success in recruiting and starting the screening of subjects for its pharmacokinetic (PK) study. This study is a crucial step in Intelligent Bio Solutions’ FDA 510(k) regulatory clearance process. The dedicated team worked diligently to ensure the study’s design met FDA standards.
On Thursday, May 30, 2024, INBS closed up 5.68% on lower-than-normal volume, triggering a Stochastic Buy Signal, a bullish indicator suggesting the stock is oversold and may present a buying opportunity. Additionally, Intelligent Bio Solutions Inc. (NASDAQ: INBS) was highlighted among Health Care Stocks in Thursday’s After-Market Session Movers by Benzinga, along with OneMedNet Corp (NASDAQ: ONMD), Abeona Therapeutics Inc. (NASDAQ: ABEO), BiomX Inc. (NYSE: PHGE), MyMD Pharmaceuticals Inc. (NASDAQ: MYMD), and Adaptimmune Therapeutics (NASDAQ: ADAP) among others, Read more.
The PK study aims to offer a detailed understanding of opiate metabolism, distribution, and excretion, particularly in human sweat. Human fingerprint sweat specimens will be collected and analyzed as part of the study. The results will be compared with those from urine, blood, and saliva specimens. The company’s Intelligent Drug Screening System leads in non-invasive drug screening solutions. Intelligent Bio Solutions expects the PK study to be completed in June.
On May 23, Intelligent Bio Solutions announced key performance indicators from its UK operations, highlighting significant growth in the drug screening sector. For the nine months ending March 31, 2024, the company reported $2.38 million in revenue, a 193% year-over-year increase, with 93% from UK operations. High-margin cartridges accounted for 49% of total revenue. Intelligent Bio Solutions provided fast, intelligent, and non-invasive drug testing to over 400 UK customers across 15 industries, acquiring 111 new accounts in the 12 months ending March 31, 2024. B2B referrals significantly drove this growth.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers